Tags : EU Marketing Approval

Biosimilars Biotech Regulatory

Mylan Receives EU Marketing Approval for Adalimumab Biosimilar “Hulio”

Shots: Hulio’s EU Marketing Approval is followed after CHMP approval that demonstrated analytical, functional, clinical and immunogenicity data similar to AbbVie’s Humira In 2018, Kyowa and Mylan signed an agreement for exclusive commercialization right of Hulio in EU, and is expect to launch on or after 16 Oct, 2018 Adalimumab is an injectable, biologic medication […]Read More